Skip to main content
Caplight Logo









Rgenta Therapeutics

Rgenta Therapeutics

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://www.rgentatx.com/

Last Round

Series A

Nov 29, 2022

Total Funding Raised

$90M

Company Overview

Rgenta Therapeutics is a biotechnology company that develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

RNA splicingsmall-molecule drugsdrug discoveryoncology therapeuticsRNA-targetingbiotechAI drug discoverysplicing modulatorundruggable targetsgenomic dataclinical-stage biotechdrug discovery platformin silico drug designpharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rgenta Therapeutics Comparables

Compare Rgenta Therapeutics with similar companies based on industry and business-model similarity.

Rgenta Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Remix Therapeutics
88%
Arrakis Therapeutics
86%
Accent Therapeutics
84%

Rgenta Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 29, 2022
SeedMay 25, 2021
SeedApr 2, 2020

Key People

Founding team and executive leadership

Simon Xi

Co-Founder and CEO

Founding Team

Rgenta Therapeutics Investors

Notable investors and investment history

Rgenta Therapeutics investors
InvestorRounds
MatrixSeries A, Seed
Legend StarSeed
Korea Investment PartnersSeries A
Kaitai CapitalSeed, Series A
MPCSeries A, Seed
Boehringer Ingelheim Venture FundSeries A, Seed
Lilly Asia VenturesSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Phase 1a/b study data released for oral MYB splicing modulator RGT-61159.

  • Apr 21, 2026

    Abstract accepted for poster presentation at the 2026 ASCO Annual Meeting.

Rgenta Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rgenta Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rgenta Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range31
Year Founded2018
Last FundingNov 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?